Prophylactic human papillomavirus vaccines: past, present and future

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Human papillomavirus (HPV) is a common, highly transmissible infection linked to various cancers in both men and women.
• HPV infections are responsible for cervical, vulval, anogenital, penile, and oropharyngeal carcinomas, as well as genital warts.

Purpose of the Study:

• To review the development of prophylactic HPV vaccines, highlighting Australian contributions.
• To examine the incorporation of HPV vaccines into Australia's National Immunisation Schedule.
• To discuss the advancements in understanding HPV virology and its role in carcinogenesis.

Main Methods:

• Review of historical data and scientific literature on HPV vaccine development.
• Analysis of early results and cross-protection data for licensed HPV vaccines.
• Examination of the vaccine's inclusion in national health policies.

Main Results:

• Prophylactic HPV vaccines were licensed in Australia in 2007, showing promising early results.
• The vaccine provides protection beyond cervical lesions, with cross-protection against multiple HPV subtypes.
• The development and integration of HPV vaccines represent a significant public health advancement.

Conclusions:

• The HPV vaccine is a crucial tool in preventing HPV-related diseases, including various carcinomas.
• Ongoing monitoring and research are essential to maximize the benefits of HPV vaccination programs.
• The vaccine's success underscores the importance of virology and immunology in cancer prevention.